2023
Cost‐effectiveness of prophylactic emicizumab versus prophylactic recombinant factor VIII in patients with moderate or mild hemophilia A without inhibitors in the United States
Potnis K, Viswanathan G, Bona R, Ito S, Kempton C, Pandya A, Krumholz H, Goshua G. Cost‐effectiveness of prophylactic emicizumab versus prophylactic recombinant factor VIII in patients with moderate or mild hemophilia A without inhibitors in the United States. American Journal Of Hematology 2023, 98: e247-e250. PMID: 37401660, DOI: 10.1002/ajh.27014.Peer-Reviewed Original Research
2021
Incidence and associated factors of sudden unexpected death in advanced cancer patients: A multicenter prospective cohort study
Ito S, Morita T, Uneno Y, Taniyama T, Matsuda Y, Kohara H, Maeda I, Nakayama T, Mori M, Investigators T. Incidence and associated factors of sudden unexpected death in advanced cancer patients: A multicenter prospective cohort study. Cancer Medicine 2021, 10: 4939-4947. PMID: 34114364, PMCID: PMC8290229, DOI: 10.1002/cam4.4030.Peer-Reviewed Original ResearchConceptsInpatient hospices/palliative care unitsAdvanced cancer patientsProspective cohort studyCohort studyPalliative care physiciansCare unitCancer patientsFunctional status assessmentSudden unexpected deathOccurrence of sudden unexpected deathMulticenter prospective cohort studyFamily caregiversHospice/palliative careCare physiciansUnexpected deathMedical staffFunctional declineMale sexKarnofsky PSStatus assessmentPhysiciansSudden deathDeathIncidencePatients